

**Cancer Society of New Zealand Auckland Northland Division  
Incorporated**

**Performance Report  
for the year ended 31 March 2023**

<b>Contents</b>	<b>Pages</b>
Directory	1
Independent auditor's report	2
Statement of service performance	4
Financial Statements	
Statements of comprehensive revenue and expense	6
Statements of changes in net assets/equity	7
Statements of financial position	8
Statements of cash flows	9
Notes to and forming part of financial statements	10

**Cancer Society of New Zealand Auckland Northland Division Incorporated  
Directory  
for the year ended 31 March 2023**

---

**DATE OF INCORPORATION** 20 February 1951

**REGISTERED OFFICE** 1 Boyle Crescent  
Grafton  
Auckland

**CHARITIES REGISTRATION NUMBER** CC22556

**INCORPORATION NUMBER** 221619

**PRESIDENT** C Kinser

**INDEPENDENT AUDITOR** BDO Auckland  
Auckland

**BANKERS** ANZ Bank  
Auckland

**SOLICITORS** Armstrong Murray  
Lawyers  
Auckland

**INDEPENDENT AUDITOR'S REPORT  
TO THE MEMBERS OF CANCER SOCIETY OF NEW ZEALAND AUCKLAND NORTHLAND DIVISION  
INCORPORATED**

## Opinions

We have audited the consolidated and separate performance reports of Cancer Society of New Zealand Auckland Northland Division Incorporated (“the Society”) and its controlled entity (together, “the Group”), which comprise the consolidated and separate financial statements on pages 6 to 20, and the consolidated statement of service performance on pages 4 to 5. The complete set of consolidated and separate financial statements comprise the consolidated and separate statements of financial position as at 31 March 2023, and the consolidated and separate statements of comprehensive revenue and expense, consolidated and separate statements of changes in net assets/equity, and consolidated and separate statements of cash flows for the year then ended, and notes to the consolidated and separate financial statements, including a summary of significant accounting policies.

### *Opinion on the Consolidated Statement of Service Performance*

In our opinion, the accompanying performance report presents fairly, in all material respects, the consolidated service performance for the year ended 31 March 2023, in accordance with the Group’s service performance criteria, in accordance with Public Benefit Entity Standards Reduced Disclosure Regime issued by the New Zealand Accounting Standards Board.

### *Qualified Opinion on the Consolidated and Separate Financial Statements*

In our opinion, except for the effects of the matter described in the *Basis for Qualified Opinion on the Consolidated and Separate Financial Statements* section of our report, the accompanying consolidated and separate financial statements present fairly, in all material respects the consolidated financial position of the Group and the separate financial position of the Society as at 31 March 2023, and their consolidated and separate financial performance and cash flows for the year then ended in accordance with Public Benefit Entity Standards Reduced Disclosure Regime (“PBE Standards RDR”) issued by the New Zealand Accounting Standards Board.

### **Basis for Qualified Opinion on the Consolidated and Separate Financial Statements**

Included in the consolidated and separate statements of comprehensive revenue and expense for the year ended 31 March 2023 is revenue from donations, appeals, grants & events and memoriam received in cash, amounting to \$734,777. Control over such revenues prior to being recorded is limited. Consequently, there were no practical audit procedures we could perform to confirm independently that all cash revenue items were properly recorded. Accordingly, we were unable to determine the completeness of revenue and the related cash flows.

We conducted our audit of the consolidated and separate financial statements in accordance with International Standards on Auditing (New Zealand) (“ISAs (NZ)”) and the audit of the consolidated statement of service performance in accordance with the ISAs (NZ) and New Zealand Auditing Standard (NZ AS) 1 *The Audit of Service Performance Information (NZ)*. Our responsibilities under those standards are further described in the *Auditor’s Responsibilities for the Audit of the Performance Report* section of our report. We are independent of the Society and Group in accordance with Professional and Ethical Standard 1 *International Code of Ethics for Assurance Practitioners (including International Independence Standards) (New Zealand)* issued by the New Zealand Auditing and Assurance Standards Board, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Other than in our capacity as auditor we have no relationship with, or interests in, the Society or its controlled entity.

## Board's Responsibilities for the Consolidated and Separate Performance Reports

The Board is responsible on behalf of the Society and Group for:

- (a) the preparation and fair presentation of the consolidated and separate financial statements and consolidated statement of service performance in accordance with Public Benefit Entity Standards RDR issued by the New Zealand Accounting Standards Board;
- (b) service performance criteria that are suitable in order to prepare service performance information in accordance with Public Benefit Entity Standards RDR; and
- (c) such internal control as those charged with governance determine is necessary to enable the preparation of the consolidated and separate financial statements and consolidated statement of service performance that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated and separate performance reports those charged with governance are responsible for assessing the Society and Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless those charged with governance either intend to liquidate the Society or Group or to cease operations, or have no realistic alternative but to do so.

## Auditor's Responsibilities for the Audit of the Consolidated and Separate Performance Reports

Our objectives are to obtain reasonable assurance about whether the consolidated and separate financial statements as a whole, and the consolidated statement of service performance are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (NZ) and NZ AS 1 will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the decisions of users taken on the basis of these consolidated and separate performance reports.

A further description of our responsibilities for the audit of the consolidated and separate performance reports is located at the XRB's website at:

<https://www.xrb.govt.nz/standards/assurance-standards/auditors-responsibilities/audit-report-13/>

This description forms part of our auditor's report.

## Who we Report to

This report is made solely to the Society's members, as a body. Our audit work has been undertaken so that we might state those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Society and the Society's members, as a body, for our audit work, for this report or for the opinions we have formed.

*BDO Auckland*

BDO Auckland  
Auckland  
New Zealand  
1 August 2023

# Cancer Society of New Zealand Auckland Northland Division Incorporated

## Statement of Service Performance

for the year ended 31 March 2023

Our role is:

To improve community well-being by reducing the impact and incidence of cancer in all communities in Auckland and Northland

Our goals are to:

- be a respected voice on cancer prevention, care and survivorship
- be a valued partner within the health sector locally, nationally and internationally
- use our resources efficiently to deliver equitable cancer outcomes for people, whānau and populations
- ensure we are anchored in our communities in the high-value services we deliver

In order to meet the mission and goals of the Cancer Society of New Zealand Auckland Northland Division Incorporated (CSAN), the organisation operates in a number of functional areas. These include;

### Support Services

Support Services employed 39 staff as at 31 March 2023 (2022 36) They include Nurses, Counsellors, Social workers, Psychologists and support staff and are primarily located at the Auckland and Whangarei offices. Clinics are carried out at Middlemore. Nurses and support staff also conduct home visits.

An equity initiative named Kia ora e Te Iwi was launched during the year. Based out of the Whangarei office, three staff have been employed to work across Māori communities on a targeted basis

The continued impact of Covid meant video calls continued to form a significant part of client contact, particularly in the first nine months of the year.

Service	Description	2023	2022
Referrals	Individuals with at least one contact with Cancer Society Support Services	3,509	3,154
Contacts in person	Interaction face to face including home visits	5,136	3,412
Contacts - Other	Includes mail, email, text, video, phone	50,778	42,643
Psychology	Psychosocial support sessions provided to patients and whanau	2,086	2,032
Driving Services	Drives provided to patients (including volunteers)	2,578	2,541

## Research

CSAN funds a range of cancer research projects and programmes directly and supporting the national Cancer Society programme. The 2022 year included a donation of \$1.1 million towards specialised equipment for the Auckland Cancer Society Research Centre.

Year	2023	2022
Research Expenditure	\$2,377,719	\$3,420,446

## Domain Lodge

Domain Lodge provides 52 rooms for patient use and a further two flats alongside the main building. The majority of these patients stay free of charge due to the provision of Te Whatu Ora's National Travel Assistance funding of \$86.96 per night, and the support of CSAN.

Year	2023	2022
Patient nights at Domain Lodge	26,411	23,139

## Volunteer Services.

Our Volunteer team arranges support in a number of areas of CSAN, particularly events. Volunteer participation increased in 2023 after being impacted by Covid in recent years. This was most noticeable for Daffodil Day, our major volunteer activity. Other activities that utilise the services of Volunteers include the Driving Service, Oncology and at Domain Lodge.

## Fundraising and Community Events.

Many CSAN fundraising events had been put on hold or modified during Covid. It was therefore a welcome return to Daffodil Day in August 2022 after being virtual the previous two years. Similarly Walking Stars was held in November 2022 after being a virtual event the previous year.

Significant Events	2023	2022
Daffodil Day	Held	Held virtually
Relay for Life – various locations	Held	Held virtually
Walking Stars	Held	Held virtually
Longest Day	Held	Held
Auckland Marathon (Charity Partner)	Held	Held (delayed)
Jump for Cancer	Held	Held

## Contribution to the Health Sector

The Cancer Society of New Zealand comprises a National Office in Wellington and six regional divisions including CSAN. Much of the advocacy work and submissions on health matters are presented by National Office. CSAN provides support and the consumer 'voice' from our regional Health Promotion/Cancer Prevention team.

**Cancer Society of New Zealand Auckland Northland Division Incorporated**  
**Statements of comprehensive revenue and expense**  
**for the year ended 31 March 2023**

	<i>Note</i>	<b>Group 2023 \$</b>	<b>Group 2022 \$</b>	<b>Society 2023 \$</b>	<b>Society 2022 \$</b>
Revenue from non-exchange transactions	2	10,794,380	15,468,344	13,365,349	15,468,344
Revenue from exchange transactions	3	1,972,944	1,922,047	1,972,944	1,922,047
Investment income	5	(1,522,090)	116,643	(663,111)	622,730
Other income		101	4,164	101	4,164
<b>Total income</b>		<b>11,245,335</b>	<b>17,511,198</b>	<b>14,675,283</b>	<b>18,017,285</b>
Administration expenses	6	3,400,091	3,496,122	3,268,860	3,361,560
Research costs		2,463,266	3,599,385	2,463,266	3,599,385
Support service expenses		2,951,180	2,705,583	2,951,180	2,705,583
Domain Lodge accommodation expenses		1,415,580	1,302,250	1,415,580	1,302,250
Fundraising & promotion costs		3,958,511	3,125,191	3,958,511	3,125,191
Health promotion costs		248,254	230,826	248,254	230,826
Grant to Davis Carr Cancer Society Endowment Trust		-	-	-	2,850,122
<b>Total expenses</b>		<b>14,436,882</b>	<b>14,459,357</b>	<b>14,305,651</b>	<b>17,174,917</b>
<b>Surplus for the year attributable to members</b>		<b>(3,191,547)</b>	<b>3,051,841</b>	<b>369,632</b>	<b>842,368</b>
<b>Net surplus and total comprehensive revenue and expense for the period attributable to members</b>		<b>(3,191,547)</b>	<b>3,051,841</b>	<b>369,632</b>	<b>842,368</b>

This statement must be read in conjunction with the notes to the accounts and the audit report on pages 2-3

**Cancer Society of New Zealand Auckland Northland Division Incorporated**  
**Statements of changes in net assets/equity**  
**for the year ended 31 March 2023**

	<i>Note</i>	<b>Available for sale assets reserve \$</b>	<b>Accumulated funds \$</b>	<b>Total \$</b>
<b>Society</b>				
<b>2022</b>				
Balance at 1 April 2021		2,515,094	27,454,067	29,969,161
Adjustment on Adoption of PBE IPSAS 41		(2,515,094)	2,515,094	-
Restated Balance at 1 April 2021		-	29,969,161	29,969,161
Net surplus and total comprehensive revenue and expense		-	842,368	842,368
<b>Balance at 31 March 2022</b>		<b>-</b>	<b>30,811,529</b>	<b>30,811,529</b>
<b>Society</b>				
<b>2023</b>				
Balance at 1 April 2022		-	30,811,529	30,811,529
Net surplus and total comprehensive revenue and expense		-	369,632	369,632
<b>Balance at 31 March 2023</b>		<b>-</b>	<b>31,181,161</b>	<b>31,181,161</b>
<b>Group</b>				
<b>2022</b>				
Balance at 1 April 2021		9,937,847	43,519,455	53,457,302
Adjustment on Adoption of PBE IPSAS 41		(9,937,847)	9,937,847	-
Restated Balance at 1 April 2021		-	53,457,302	53,457,302
Net surplus and total comprehensive revenue and expense		-	3,051,841	3,051,841
<b>Balance at 31 March 2022</b>		<b>-</b>	<b>56,509,143</b>	<b>56,509,143</b>
<b>Group</b>				
<b>2023</b>				
Balance at 1 April 2022		-	56,509,143	56,509,143
Net surplus and total comprehensive revenue and expense		-	(3,191,547)	(3,191,547)
<b>Balance at 31 March 2023</b>		<b>-</b>	<b>53,317,596</b>	<b>53,317,596</b>



**Cancer Society of New Zealand Auckland Northland Division Incorporated**  
**Statements of financial position**  
**as at 31 March 2023**

	<b>Note</b>	<b>Group 2023 \$</b>	<b>Group 2022 \$</b>	<b>Society 2023 \$</b>	<b>Society 2022 \$</b>
<b>Equity</b>					
Accumulated funds		53,317,596	56,509,143	31,181,161	30,811,529
Available for sale assets reserve		-	-	-	-
<b>Total Equity</b>		<b>53,317,596</b>	<b>56,509,143</b>	<b>31,181,161</b>	<b>30,811,529</b>
<b>Non-current liabilities</b>					
Employee benefits	13	-	100,442	-	100,442
<b>Total non-current liabilities</b>		<b>-</b>	<b>100,442</b>	<b>-</b>	<b>100,442</b>
<b>Current liabilities</b>					
Trade payables - exchange transactions	12	1,295,303	1,850,663	1,263,046	1,848,311
Income in advance		143,630	40,200	143,630	40,200
Employee benefits	13	297,765	365,231	297,765	365,231
<b>Total current liabilities</b>		<b>1,736,698</b>	<b>2,256,094</b>	<b>1,704,441</b>	<b>2,253,742</b>
<b>Total liabilities</b>		<b>1,736,698</b>	<b>2,356,536</b>	<b>1,704,441</b>	<b>2,354,184</b>
<b>Total equity and liabilities</b>		<b>55,054,295</b>	<b>58,865,679</b>	<b>32,885,602</b>	<b>33,165,713</b>
<b>Non-current assets</b>					
Investments	9	40,727,518	44,823,354	18,161,741	19,123,388
Property, plant and equipment	10	3,458,363	3,864,138	3,458,363	3,864,138
Properties held for strategic purposes	11	5,098,328	5,168,253	5,098,328	5,168,253
<b>Total non-current assets</b>		<b>49,284,209</b>	<b>53,855,745</b>	<b>26,718,432</b>	<b>28,155,779</b>
<b>Current assets</b>					
Cash and cash equivalents	7	1,518,910	2,096,729	1,518,910	2,096,729
Investments	9	4,000,000	2,551,540	4,000,000	2,551,540
Receivables - exchange transactions	8	201,055	248,914	598,139	248,914
GST receivable		50,121	112,751	50,121	112,751
<b>Total current assets</b>		<b>5,770,086</b>	<b>5,009,934</b>	<b>6,167,170</b>	<b>5,009,934</b>
<b>Total assets</b>		<b>55,054,295</b>	<b>58,865,679</b>	<b>32,885,602</b>	<b>33,165,713</b>

For and on behalf of the board:

Dated: 1 August 2023

Chief Executive

President

**Cancer Society of New Zealand Auckland Northland Division Incorporated**  
**Statements of cash flows**  
**for the year ended 31 March 2023**

	<i>Note</i>	<b>Group 2023 \$</b>	<b>Group 2022 \$</b>	<b>Society 2023 \$</b>	<b>Society 2022 \$</b>
<b>Cash flows from operating activities</b>					
Cash provided from:					
Receipts from public, services and other sources		12,530,116	17,309,331	15,101,085	17,309,331
Interest received		356,488	166,673	96,125	166,673
Dividends received		10,725	10,233	10,725	10,233
		<u>12,897,329</u>	<u>17,486,237</u>	<u>15,207,935</u>	<u>17,486,237</u>
Cash applied to:					
Payments to suppliers and to employees		(14,100,908)	(12,510,976)	(14,006,656)	(15,457,871)
<b>Net cash from operating activities</b>		<u>(1,203,579)</u>	<u>4,975,261</u>	<u>1,201,279</u>	<u>2,028,366</u>
<b>Cash flows from investing activities</b>					
Cash provided from:					
Proceeds from sale of property, plant & equipment		40,870	19,130	40,870	19,130
Proceeds from sale of investments		2,606,398	-	201,540	-
		-	-	-	-
Cash applied to:					
Purchase of investments		(1,650,000)	(4,446,895)	(1,650,000)	(1,500,000)
Purchase of property, plant & equipment		(371,508)	(252,367)	(371,508)	(252,367)
<b>Net cash from investing activities</b>		<u>625,760</u>	<u>(4,680,132)</u>	<u>(1,779,098)</u>	<u>(1,733,237)</u>
<b>Net increase in cash, and cash equivalents</b>		(577,819)	295,129	(577,819)	295,129
Cash and cash equivalents at the beginning of the year		2,096,729	1,801,600	2,096,729	1,801,600
<b>Cash and cash equivalents at the end of the year</b>	7	<u>1,518,910</u>	<u>2,096,729</u>	<u>1,518,910</u>	<u>2,096,729</u>

**Cancer Society of New Zealand Auckland Northland Division Incorporated**  
**Notes to and forming part of the Financial Statements**  
**for the year ended 31 March 2023**

---

**1 Statement of significant accounting policies for the year**

**Reporting entity**

The Cancer Society of New Zealand Auckland Northland Division Incorporated ("the Society") is an incorporated society incorporated in New Zealand under the Incorporated Societies Act 1908 and registered under the Charities Act 2005. The Society is a public benefit entity for the purposes of financial reporting. The Society is domiciled and operates in New Zealand.

The primary objective of the Society is to improve community well-being by reducing the incidence and impact of Cancer. The Society also supports research, fosters and advocates health promotion, and provides support and comfort to people suffering from cancer and their whanau.

**Group**

The group consolidated performance report includes the Society and the Davis Carr Cancer Society Endowment Trust as described in note 14.

**Statement of compliance and basis of preparation**

The performance report has been prepared in accordance with the Charities Act 2005 and New Zealand Generally Accepted Accounting Practice ("NZ GAAP"). They comply with Public Benefit Entity International Public Sector Accounting Standards ("PBE IPSAS") and other applicable Financial Reporting Standards, as appropriate for Tier 2 not-for-profit public benefit entities ("Tier 2 PBE Standards"), for which all reduced disclosure regime exemptions have been adopted. The Group and Society are eligible to apply Tier 2 PBE Standards because they both have annual expenditure less than \$30 million and they are not publicly accountable.

These financial statements have been prepared under the historical cost basis except for the following material items in the statement of financial position, which are measured at fair value:

- Financial assets at fair value through surplus or deficit. (note 9).

The financial statements are presented in New Zealand dollars (\$), which is the functional currency of the Society and Group's presentation currency, rounded to the nearest dollar. There has been no change in the functional currency of the Society during the year.

**Foreign currency**

Transactions in foreign currencies are converted at the New Zealand rate of exchange at the date of transaction. At the reporting date, any foreign currency monetary assets and liabilities are translated at the exchange rate at that date and any resulting exchange variations are included in surplus or deficit.

Foreign currency differences arising on retranslation are recognised in surplus or deficit, except for differences arising on the retranslation of available-for-sale equity investments (except on impairment in which case foreign currency differences that have been recognised in other comprehensive revenue and expense are reclassified to surplus or deficit), which are recognised in other comprehensive revenue and expense.

**Critical accounting estimates and assumptions**

The preparation of the performance report requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period which the estimates are revised and in any future periods affected.

Information about significant areas of estimation uncertainty and critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements is noted below:

- The Board have judged that the Society and Group's investment properties are held for strategic purpose and therefore the properties are accounted for under PBE IPSAS 17 Property, Plant and Equipment and not PBE IPSAS 16 Investment Property (refer to note 11). The Society has adopted a strategy of purchasing properties adjacent to its Domain Lodge property, as they become available for sale, for the purpose of providing for the future development of Domain Lodge, having regard to its close proximity to the Auckland Public Hospital.

**Cancer Society of New Zealand Auckland Northland Division Incorporated**  
**Notes to and forming part of the Financial Statements**  
**for the year ended 31 March 2023**

**1 Statement of significant accounting policies for the year (continued)**

- The Board have judged that the Davis Carr Cancer Society Endowment Trust (Trust) is a special purpose entity controlled by the Society as the board appoints the trustees and the Society is the beneficiary of the Trust (refer to note 14).
- Revenue from bequests and legacies: Where there is a life interest associated with the bequest or legacy or the bequest or the legacy is being contested, the revenue from the bequest and legacy is not recognised until the revenue is measurable and probable.
- Statement of Service Performance. In compiling the Group's Performance report, the Group made judgements in relation to which outcomes and outputs best reflect the achievement of the Group's primary purposes. One Statement of Service Performance has been presented covering the Society and Group on the basis the primary aims and objectives of both are aligned.

**Changes in accounting policies**

The accounting policies have been applied consistently to all periods presented in these financial statements.

The Society adopted PBE FRS 48 *Service Performance Reporting* during the year which was effective for periods beginning on or after 1 January 2022. PBE FRS 48 requires specific disclosures for the reporting of service performance information which have been provided in the statement of service performance. Comparatives have been presented as required by the standard.

**2 Revenue from non-exchange transactions**

	<b>Group 2023</b>	<b>Group 2022</b>	<b>Society 2023</b>	<b>Society 2022</b>
	\$	\$	\$	\$
Bequest and legacies				
- For general purposes	2,071,456	3,486,592	2,071,456	3,486,592
- For research	1,766,542	5,195,602	1,766,542	5,195,602
Donations, appeals, grants & events and memoriam	6,956,382	6,701,056	9,527,351	6,701,056
Grant from COVID wage subsidy and general COVID support	-	85,094	-	85,094
<b>Total revenue from non-exchange transactions</b>	<b>10,794,380</b>	<b>15,468,344</b>	<b>13,365,349</b>	<b>15,468,344</b>

Non-exchange transactions are those where the Group receives an inflow of resources (i.e. cash and other tangible or intangible items) but provides no (or nominal) direct consideration in return.

The following specific recognition criteria in relation to the Group's non-exchange transaction revenue streams must also be met before revenue is recognised.

Fundraising

The Group's fundraising activities involve public cash collections. Fundraising non-exchange revenue is recognised at the point at which cash is received.

Volunteer service

The Society would be unable to operate without the extensive volunteer service it receives from members, supporters, service groups and the general public. These services relate to both raising revenue and service delivery. Principal volunteer services include street collectors for Daffodil Day, entrants and organisers of Relay for Life events, numerous small fund raising events sponsored by individuals and service clubs, board members who provide governance to the Group, drivers who transport cancer patients to their treatment and meal service providers who deliver meals to cancer patients homes. Generally, the contributions made by individuals is not recorded in detail. No complete record of hours is available and the diverse nature of contribution and individuals involved means it is not possible to reliably value the services they provide. For this reason the value of volunteer services is not recognised as revenue.

Grants, donations, legacies and bequests

The recognition of non-exchange revenue from grants, donations, legacies and bequests depends on the nature of any stipulations attached to the inflow of resources received, and whether this creates a liability (i.e. present obligation) rather than the recognition of revenue.

**Cancer Society of New Zealand Auckland Northland Division Incorporated**  
**Notes to and forming part of the Financial Statements**  
**for the year ended 31 March 2023**

**2 Revenue from non-exchange transactions (continued)**

Stipulations that are 'conditions' specifically require the Group to return the inflow of resources received if they are not utilised in the way stipulated, resulting in the recognition of a non-exchange liability that is subsequently recognised as non-exchange revenue as and when the 'conditions' are satisfied.

Stipulations that are 'restrictions' do not specifically require the Group to return the inflow of resources received if they are not utilised in the way stipulated, and therefore do not result in the recognition of a non-exchange liability, which results in the immediate recognition of non-exchange revenue.

**3 Revenue from exchange transactions**

	<b>Group 2023</b>	<b>Group 2022</b>	<b>Society 2023</b>	<b>Society 2022</b>
	\$	\$	\$	\$
Services income	154,759	139,005	154,759	139,005
Revenue from property rentals	356,897	345,201	356,897	345,201
Revenue from Domain Lodge accommodation	1,461,288	1,437,841	1,461,288	1,437,841
<b>Total revenue from exchange transactions</b>	<b>1,972,944</b>	<b>1,922,047</b>	<b>1,972,944</b>	<b>1,922,047</b>

Rendering of services

The Group's services includes information and health promotion services provided.

Revenue from services rendered is recognised in surplus or deficit in proportion to the stage-of-completion of the transaction at the reporting date. The stage of completion is assessed by reference to work performed at reporting date for services income.

Amounts received in advance for services to be provided in future periods are recognised as a liability until such time as the service is provided.

Rental income on properties held for strategic purposes

Rental income from properties held for strategic purposes is recognised in surplus or deficit on a straight-line basis over the term of the lease. Lease incentives granted are recognised as an integral part of the total rental income, over the term of the lease.

Revenue from Domain Lodge accommodation

Revenue from Domain Lodge accommodation (rental of rooms) is recognised in surplus or deficit when rooms are occupied.

**4 Employee benefit costs**

	<b>Group 2023</b>	<b>Group 2022</b>	<b>Society 2023</b>	<b>Society 2022</b>
	\$	\$	\$	\$
Salaries and wages	5,303,485	4,935,891	5,303,485	4,935,891
Contributions to medical insurance	39,824	47,212	39,824	47,212
<b>Total employee benefit costs</b>	<b>5,343,309</b>	<b>4,983,103</b>	<b>5,343,309</b>	<b>4,983,103</b>

**Cancer Society of New Zealand Auckland Northland Division Incorporated**  
**Notes to and forming part of the Financial Statements**  
**for the year ended 31 March 2023**

**5 Investment income**

Recognised in revenue	Group 2023 \$	Group 2022 \$	Society 2023 \$	Society 2022 \$
<i>Dividend income on financial assets at fair value through surplus or deficit</i>				
Dividends	10,725	10,233	10,725	10,233
<i>Interest income from financial assets at amortised cost</i>				
Interest on term deposits and bank balance	104,863	98,129	104,863	98,129
<i>Interest/distribution income on financial assets at fair value through surplus or</i>				
Interest/distribution income on bonds and managed	573,513	380,647	58,931	67,497
<i>Revaluation of investments at fair value through surplus or deficit</i>				
Stock, bonds and managed funds	(2,211,191)	(372,366)	(837,630)	446,871
<b>Total financial income</b>	<b>(1,522,090)</b>	<b>116,643</b>	<b>(663,111)</b>	<b>622,730</b>

Investment income comprises interest income on financial assets, gains on financial assets at fair value through surplus or deficit and dividend income. Interest income is recognised as it accrues in surplus or deficit, using the effective interest method. Income from dividends is recognised when the Group's right to receive payment is established, and the amount can be reliably measured.

**6 Administration expenses**

	Group 2023 \$	Group 2022 \$	Society 2023 \$	Society 2022 \$
<i>Administration expenses include the following:</i>				
Audit fee (for the audit of the financial statements)	40,352	34,713	39,280	26,675
Depreciation on property, plant & equipment (note 11)	583,967	552,371	583,967	552,371
Depreciation on properties held for strategic purposes (note	69,925	69,925	69,925	69,925
Cancer Society Levy	873,851	882,884	873,851	882,884
Salaries and wages	654,109	614,224	654,109	614,224
Computer costs	277,725	381,970	277,725	381,970
Other administration expenses	900,162	960,035	770,003	833,511
<b>Total administration expenses</b>	<b>3,400,091</b>	<b>3,496,122</b>	<b>3,268,860</b>	<b>3,361,560</b>

**7 Cash and cash equivalents**

	Group 2023 \$	Group 2022 \$	Society 2023 \$	Society 2022 \$
Cash on hand	700	1,050	700	1,050
Cash at bank on call	1,518,210	2,096,029	1,518,210	2,096,029
<b>Total cash and cash equivalents</b>	<b>1,518,910</b>	<b>2,097,079</b>	<b>1,518,910</b>	<b>2,097,079</b>

**Cancer Society of New Zealand Auckland Northland Division Incorporated**  
**Notes to and forming part of the Financial Statements**  
**for the year ended 31 March 2023**

**8 Receivables - exchange transactions**

	<b>Group 2023</b>	<b>Group 2022</b>	<b>Society 2023</b>	<b>Society 2022</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
Accounts receivable	174,413	245,660	571,497	245,660
Other receivable	14,984	334	14,984	334
Accrued bank interest	11,658	2,920	11,658	2,920
<b>Total receivables - exchange transactions</b>	<b>201,055</b>	<b>248,914</b>	<b>598,139</b>	<b>248,914</b>

As at 31 March 2023 and 2022 there were no impairment allowances.

**9 Investments**

	<b>Group 2023</b>	<b>Group 2022</b>	<b>Society 2023</b>	<b>Society 2022</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
<i>Current investments</i>				
Financial assets at amortised cost				
-term deposits with maturity under 12 months	4,000,000	2,350,000	4,000,000	2,350,000
Financial assets at fair value through surplus or deficit				
-bonds	-	201,540	-	201,540
	<b>4,000,000</b>	<b>2,551,540</b>	<b>4,000,000</b>	<b>2,551,540</b>
<i>Term investments</i>				
Financial assets at fair value through surplus or deficit				
- shares	638,970	701,886	638,970	701,886
Financial assets at fair value through surplus or deficit				
- managed funds	40,088,548	44,121,468	17,522,771	18,421,502
	<b>40,727,518</b>	<b>44,823,354</b>	<b>18,161,741</b>	<b>19,123,388</b>

**Financial assets at amortised cost - term deposits**

The term deposits held by the Society are managed by ANZ Bank New Zealand Limited. The average interest rate of the term deposits held at 31 March 2023 is 4.65 percent (2022:3.30 percent).

**Financial assets at fair value through surplus or deficit - bonds**

**Group and Society**

Interest-bearing financial assets at fair value through surplus or deficit with a carrying amount of \$nil as at 31 March 2023 (2022: \$201,540) had a stated interest rate of 4 percent (2022: 4 percent) and matured in 2022.

**Financial assets at fair value through surplus or deficit - shares**

The shares held by the Society are listed on the New Zealand and London stock exchanges.

**Financial assets at fair value through surplus or deficit - investments in managed funds**

**Group**

The investments held by the Society and Trust in unit funds are managed respectively by ANZ Investments and Nikko Asset Management New Zealand Limited and the Boards in accordance with the Statement of Investment Policy and Objectives.

The fair value for the various managed funds financial assets at fair value through surplus or deficit is determined as follows:

Cash funds - at face value of the amounts held

Listed government and local government securities - by reference to quoted bid price

Unlisted investments - at valuation based on arm's length transactions, reference to other instruments that have substantially the same characteristics, discounted cash flow analysis and other pricing models

Unit trusts - by reference to the quoted bid price.

**Cancer Society of New Zealand Auckland Northland Division Incorporated**  
**Notes to and forming part of the Financial Statements**  
**for the year ended 31 March 2023**

**10 Property, plant and equipment**

	Land	Building	Plant & Equipment	Computers	Motor Vehicles	Total
Group & Society	\$	\$	\$		\$	\$
<b>Cost</b>						
<b>Balance at 1 April 2022</b>	300,944	12,241,748	209,967	366,310	428,218	13,547,187
Additions	-	-	-	98,557	87,197	185,754
Disposals	-	-	-	-	(63,026)	(63,026)
<b>Balance at 31 March 2023</b>	<u>300,944</u>	<u>12,241,748</u>	<u>209,967</u>	<u>464,867</u>	<u>452,389</u>	<u>13,669,915</u>
<b>Accumulated depreciation</b>						
<b>Balance at 1 April 2022</b>	-	9,133,478	52,932	236,544	260,095	9,683,049
Depreciation for the year	-	408,058	38,751	90,284	46,874	583,967
Release on disposal	-	-	-	-	(55,464)	(55,464)
<b>Balance at 31 March 2023</b>	<u>-</u>	<u>9,541,536</u>	<u>91,683</u>	<u>326,828</u>	<u>251,505</u>	<u>10,211,552</u>
<b>Carrying amounts</b>						
<b>At 31 March 2022</b>	<u>300,944</u>	<u>3,108,270</u>	<u>157,035</u>	<u>129,766</u>	<u>168,123</u>	<u>3,864,138</u>
<b>At 31 March 2023</b>	<u>300,944</u>	<u>2,700,212</u>	<u>118,284</u>	<u>138,039</u>	<u>200,884</u>	<u>3,458,363</u>

Items of property plant and equipment are initially measured at cost, except those acquired through non-exchange transactions which are instead measured at fair value as their deemed cost at initial recognition.

Property, plant and equipment are shown at cost, less accumulated depreciation and impairment losses. All of the Group's items of property plant and equipment are subsequently measured in accordance with the cost model.

*Subsequent costs*

Subsequent expenditure is capitalised only when it is probable that the future economic benefits associated with the expenditure will flow to the Group. Ongoing repairs and maintenance is expensed as incurred.

*Depreciation*

Depreciation is provided on a straight-line basis on all property, plant and equipment at rates that will write off the cost of the assets to their estimated residual values over their useful lives. Depreciation is charged to surplus or deficit. Land is not depreciated. The useful lives and associated depreciation rates of major classes of assets have been estimated for current and prior period as follows:

Asset	Economic Life
Plant and Equipment	5 years
Computer equipment	3 years
Motor vehicles	6.7 years
Buildings	30 years

Depreciation methods, useful lives, and residual values are reviewed at reporting date and adjusted if appropriate.

**11 Properties held for strategic purposes**

	Land	Buildings	Total
<b>Group &amp; Society</b>			
<b>Cost</b>			
<b>Balance at 1 April 2022</b>	4,175,651	2,097,760	6,273,411
Additions	-	-	-
<b>Balance at 31 March 2023</b>	<u>4,175,651</u>	<u>2,097,760</u>	<u>6,273,411</u>
<b>Accumulated depreciation</b>			
<b>Balance at 1 April 2022</b>	-	1,105,158	1,105,158
Depreciation for the year	-	69,925	69,925
<b>Balance at 31 March 2023</b>	<u>-</u>	<u>1,175,083</u>	<u>1,175,083</u>
<b>Carrying amounts</b>			
<b>At 31 March 2022</b>	<u>4,175,651</u>	<u>1,062,527</u>	<u>5,238,178</u>
<b>At 31 March 2023</b>	<u>4,175,651</u>	<u>922,677</u>	<u>5,098,328</u>



**Cancer Society of New Zealand Auckland Northland Division Incorporated**  
**Notes to and forming part of the Financial Statements**  
**for the year ended 31 March 2023**

**11 Properties held for strategic purposes (continued)**

Properties held for strategic purposes comprises a number of domestic properties that are used for accommodation purposes.

Properties which are held to meet service delivery objectives are accounted for under PBE IPSAS 17 Property, Plant and Equipment. Refer to "property, plant and equipment" above.

Asset	Economic Life	
Buildings	30 years	Straight Line Method

The residual value, depreciation method and useful life of buildings is reviewed, and adjusted if applicable, at each financial year-end.

**12 Trade payables - exchange transactions**

	<b>Group 2023</b>	<b>Group 2022</b>	<b>Society 2023</b>	<b>Society 2022</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
Trade payables from exchange transactions	1,295,303	1,850,663	1,263,046	1,848,311
<b>Total trade payables - exchange transactions</b>	<b>1,295,303</b>	<b>1,850,663</b>	<b>1,263,046</b>	<b>1,848,311</b>

**13 Employee benefit liabilities**

	<b>Group 2023</b>	<b>Group 2022</b>	<b>Society 2023</b>	<b>Society 2022</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
<i>Current</i>				
Current portion of long-service leave (long term employee b	-	5,034	-	5,034
Holiday pay accrual (short term employee benefit)	295,542	306,309	295,542	306,309
Accrued expense (short term employee benefit)	2,223	53,888	2,223	53,888
<b>Total current employee benefit liabilities</b>	<b>297,765</b>	<b>365,231</b>	<b>297,765</b>	<b>365,231</b>
<i>Non-current</i>				
Non current portion of long-service leave	-	100,442	-	100,442
<b>Total non-current employee benefit liabilities</b>	<b>-</b>	<b>100,442</b>	<b>-</b>	<b>100,442</b>
<b>Total employee benefit liabilities</b>	<b>297,765</b>	<b>465,673</b>	<b>297,765</b>	<b>465,673</b>

Short-term employee benefits

Employee benefits that the Group expects to be settled wholly within 12 months of reporting date are measured at nominal values based on accrued entitlements at current rates of pay on an undiscounted basis.

These include salaries and wages accrued up to reporting date, annual leave earned to, but not yet taken at reporting date, expected to be settled within 12 months.

Long-term employee benefits

Other employee benefits that are not expected to be settled wholly within 12 months after the end of the reporting period are presented as non-current liabilities.

Provision is made for benefits accruing to employees in respect of long service leave based on the probability that settlement will be required.

Provisions made in respect of employee benefits which are not expected to be settled within 12 months are measured as the present value of the estimated future cash outflows to be made by the Group in respect of services provided by employees up to reporting date.

**Cancer Society of New Zealand Auckland Northland Division Incorporated**  
**Notes to and forming part of the Financial Statements**  
**for the year ended 31 March 2023**

**14 Group entity**

The Society established the Davis Carr Cancer Society Endowment Trust (the Trust) on 31 March 2008 to maintain and develop Domain Lodge, assist with the work and activities of the Society and provide funds for cancer research and treatment and assistance to those with cancer. The Society has the power to govern the financial and operating policies of the Trust so as to benefit from the Trust's activities. The Board have judged that the Trust is a Group entity controlled by the Society as the Board appoints the trustees and the Society is the beneficiary of the Trust.

The reporting date for the Trust is 31 March. The principal activity of the Trust is investment.

**Basis of consolidation**

*Controlled entities*

Controlled entities are entities controlled by the Group, being where the Group has power to govern the financial and operating policies of another entity so as to benefit from that entity's activities. The financial statements of the Group's controlled entities are included in the financial statements from the date that control commences until the date that control ceases.

Subsequent changes in a controlled entity that do not result in a loss of control are accounted for as transactions with controllers of the controlling entity in their capacity as controllers, within net assets/equity.

*Transactions eliminated on consolidation*

Intra-group balances, and any unrealised income and expenses arising from intra-group transactions are eliminated in preparing the consolidated financial statements.

**15 Related party transactions**

*The following transactions were carried out with related parties during the year.*

(1) Cancer Society of New Zealand Incorporated is partly funded by the Society. The Society is entitled to representation on the board of the Cancer Society of New Zealand Incorporated. In 2023 the Society paid administration and research levies of \$1,146,184 which is equal to 35% of the total divisional levy (2022: \$1,061,824).

(2) In 2023, the Society received grants totalling \$2,570,969 from the Cancer Society Davis Carr Endowment Trust (the "Trust"). (2022: Paid \$2,850,122). The balance as at 31 March 2023 owing to the Society is \$397,084 (2022: \$37,157).

(3) In the current year, the Waikato/ Bay Of Plenty Division Cancer Society of New Zealand (Incorporated) paid the Society \$147,516 (2022: \$132,552) for fundraising expertise and services .

(4) In 2022, the Society paid \$50,555 to Cancer Society Wellington Division for call centre services (2022: \$50,555).

There are no fees paid to any board member.

**Key management personnel**

The Directors of the Society, Trustees of the Trust and executive team of the Society are considered to be the key management personnel of the Group and Society. Directors of the Society and Trustees of the Trust receive no remuneration.

<b>Group and Society</b>	<b>2022</b>	<b>Number of</b>	<b>2021</b>	<b>Number of</b>
	<b>\$</b>	<b>individuals</b>	<b>\$</b>	<b>individuals</b>
Compensation to key management personnel:				
Short term employee benefits	902,626	7	852,294	6
	<u>902,626</u>		<u>852,294</u>	

**Cancer Society of New Zealand Auckland Northland Division Incorporated**  
**Notes to and forming part of the Financial Statements**  
**for the year ended 31 March 2023**

**16 Financial instruments**

**Fair values**

All financial instruments are recognised in the statement of financial position and are stated at carrying amounts that are also a reasonable approximation of their fair values.

**Classification of financial instruments**

	<b>Group 2023</b>	<b>Group 2022</b>	<b>Society 2023</b>	<b>Society 2022</b>
	\$	\$	\$	\$
<b>Current financial assets</b>				
<i>Financial assets at amortised cost</i>				
Cash and cash equivalents	1,518,910	2,096,729	1,518,910	2,096,729
Term deposits with maturity under 12 months	4,000,000	2,350,000	4,000,000	2,350,000
Accounts receivable	174,413	245,660	571,497	245,660
Other receivables	14,984	334	14,984	334
Accrued bank interest	11,658	2,920	11,658	2,920
<b>Non current financial assets</b>				
<i>Financial assets at fair value through surplus or deficit</i>				
-bonds	-	201,540	-	201,540
-shares	638,970	701,886	638,970	701,886
-managed funds	40,088,548	44,121,468	17,522,771	18,401,502
<b>Current financial liabilities</b>				
<i>Financial liabilities measured at amortised cost</i>				
Trade payables	1,295,303	1,850,663	1,263,046	1,848,311

Financial assets and financial liabilities are recognised when the Group becomes a party to the contractual provisions of the financial instrument.

The Group derecognises a financial instrument when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. Any interest in transferred financial assets that is created or retained by the Group is recognised as a separate asset or liability.

The Group derecognises a financial liability when its contractual obligations are discharged, cancelled, or expire.

Financial instruments are initially measured at fair value, plus for those financial instruments not subsequently measured at fair value through surplus or deficit, directly attributable transaction costs.

Subsequent measurement is dependent on the classification of the financial instrument, and is specifically detailed in the accounting policies below.

**Financial assets**

The Society and Group's financial assets are classified as either financial assets at amortised cost, or financial assets at fair value through surplus or deficit.

The classification of the financial assets are determined at initial recognition .

The categorisation determines subsequent measurement and where any resulting income and expense is recognised. The categorisation is on the basis of both:

- (a) The entity's management model for financial assets; and
- (b) The contractual cash flow characteristics of the financial asset.

*Financial assets at amortised cost*

A financial asset is measured at amortised cost if the financial asset is held within a management model whose objective is to hold financial assets in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

**16 Financial instruments (continued)**

After initial recognition, these are measured at amortised cost using the effective interest rate method, less any allowance for impairment.

The Group's cash and cash equivalents, term deposits, and receivables fall into this category of financial instruments.

Cash and cash equivalents represent highly liquid investments that are readily convertible into a known amount of cash with an insignificant risk of changes in value, with original maturities of three months or less.

Term deposits are those cash balances with original maturities of more than three months. Where a term deposit matures within 12 months, it is classified as a current asset. All other term deposits are classified as non-current assets.

*Financial assets at fair value through surplus or deficit*

Financial assets classified at fair value through surplus or deficit are subsequently measured at fair value with gains or losses being recognised in surplus or deficit.

Financial assets at fair value through surplus or deficit include equity and debt securities, and managed fund investments. These investments are classified as financial assets at fair value through surplus or deficit because they are managed and their performance is evaluated on a fair value basis and they do not meet the criteria for any other category of financial instruments.

**Financial Liabilities**

Financial liabilities include payables (from exchange and non-exchange transactions).

The Group's financial liabilities are subsequently measured at amortised cost using the effective interest rate method.

**Impairment of non-derivative financial assets**

Financial assets as amortised cost are assessed at each reporting date to determine whether there is objective evidence that they are impaired. A financial asset is impaired if there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset. Impairment is recognised in surplus or deficit.

**17 Financial commitments and operating leases**

**Leases as lessee**

At balance date the Group and Society had operating lease commitments of \$nil (2022 - \$nil).

**Financial commitments:**

The group has resolved to provide support to the following entities in the next financial year:

	<b>Next 12 months</b>	<b>Between 1 - 5 years</b>	<b>Beyond 5 years</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
<b>Group and Society 2023</b>			
Cancer Trials NZ - clinical trials	243,000	-	-
ACS Research Centre funding and other fundraising costs	2,200,000	-	-
	<u>2,443,000</u>	<u>-</u>	<u>-</u>
<b>Group and Society 2022</b>			
Cancer Trials NZ - clinical trials	243,000	-	-
ACS Research Centre funding and other fundraising costs	2,126,000	-	-
	<u>2,369,000</u>	<u>-</u>	<u>-</u>

**18 Contingencies**

**Contingent liability**

The Group and Society have no contingent liabilities as at 31 March 2023 (2022 - \$nil).

**Contingent assets**

At reporting date the Group and Society has received intimation concerning bequests which will be received in the future. These bequests cannot be quantified by the Group and Society as at reporting date due to fact that they cannot be reliably measured. A register is maintained of all the future bequests receivable.

This is available from the Domain Lodge, 1 Boyle Crescent, Grafton.

**19 Events after the reporting date**

There are no events subsequent to balance date requiring disclosure in this performance report.